Literature DB >> 29429039

Health Survey of Adults with Neurofibromatosis 1 Compared to Population Study Controls.

Krister W Fjermestad1,2, Livø Nyhus3, Øivind J Kanavin3, Arvid Heiberg4, Lise B Hoxmark3.   

Abstract

Neurofibromatosis type 1 (NF1) is a genetic, autosomal dominant multi-organ disease characterized by susceptibility to tumor formation, changes in skin pigmentation, skeletal abnormalities, and neuropsychological deficits. Clinical studies have shown impaired health-related quality of life (HQoL) in adults with NF1. However, little is known about HQoL in non-clinical NF1 samples. We conducted a cross-sectional self-report survey of 142 persons with NF1 (M age = 50.3 years, SD = 12.0, range 32 to 80; 62.0% females) recruited from non-clinical settings. Several HQoL domains, including life satisfaction, mental health, sleep, pain, gastrointestinal problems, oral health, and social support, were compared between the NF1 sample and 46,293 controls from the HUNT3 population study. We also examined gender differences within the NF1 sample and predictors of HQoL. Compared to controls, the NF1 sample reported significantly poorer life satisfaction, mental health, sleep, and oral health, and more pain, gastrointestinal problems, comorbid diseases, and memory problems. Several HQoL domains were significantly correlated. Mental health was the only unique significant predictor of overall life satisfaction. Women with NF1 reported significantly more mental health, sleep, and pain problems than men with NF1. Mental health assessment and management should be integrated into clinical care of persons with NF1 to potentially improve their HQoL.

Entities:  

Keywords:  Mental health; NF1; Neurofibromatosis; Quality of life

Mesh:

Year:  2018        PMID: 29429039     DOI: 10.1007/s10897-018-0229-5

Source DB:  PubMed          Journal:  J Genet Couns        ISSN: 1059-7700            Impact factor:   2.537


  39 in total

1.  Treatment of ADHD in neurofibromatosis type 1.

Authors:  Victor-F Mautner; Lan Kluwe; Sarang D Thakker; Robert A Leark
Journal:  Dev Med Child Neurol       Date:  2002-03       Impact factor: 5.449

2.  Knowledge and Self-Esteem of Individuals with Neurofibromatosis Type 1 (NF1).

Authors:  Kayla Rosnau; S Shahrukh Hashmi; Hope Northrup; John Slopis; Sarah Noblin; Myla Ashfaq
Journal:  J Genet Couns       Date:  2016-11-04       Impact factor: 2.537

3.  Neuropsychological deficits in adults with neurofibromatosis type 1.

Authors:  M E Zöller; B Rembeck; L Bäckman
Journal:  Acta Neurol Scand       Date:  1997-04       Impact factor: 3.209

4.  Voice-related quality of life in adults with neurofibromatosis type 1.

Authors:  Marjan Cosyns; Geert Mortier; Sandra Janssens; John Van Borsel
Journal:  J Voice       Date:  2011-05-07       Impact factor: 2.009

5.  Health-related quality of life measured by the EORTC QLQ-C30--reference values from a large sample of Swedish population.

Authors:  H Michelson; C Bolund; B Nilsson; Y Brandberg
Journal:  Acta Oncol       Date:  2000       Impact factor: 4.089

6.  Neuropsychological profile in adults with neurofibromatosis type 1 compared to a control group.

Authors:  M-J Descheemaeker; E Plasschaert; J-P Frijns; E Legius
Journal:  J Intellect Disabil Res       Date:  2012-10-24

7.  Epilepsy in individuals with neurofibromatosis type 1.

Authors:  Adam P Ostendorf; David H Gutmann; Judith L Z Weisenberg
Journal:  Epilepsia       Date:  2013-08-29       Impact factor: 5.864

8.  Sleep disturbance as part of the neurofibromatosis type 1 phenotype in adults.

Authors:  Guy D Leschziner; John F Golding; Rosalie E Ferner
Journal:  Am J Med Genet A       Date:  2013-05-01       Impact factor: 2.802

Review 9.  Sex differences in sleep: impact of biological sex and sex steroids.

Authors:  Jessica A Mong; Danielle M Cusmano
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2016-02-01       Impact factor: 6.237

10.  Constipation in adults with neurofibromatosis type 1.

Authors:  Cecilie Ejerskov; Klaus Krogh; John R Ostergaard; Janne L Fassov; Annette Haagerup
Journal:  Orphanet J Rare Dis       Date:  2017-08-16       Impact factor: 4.123

View more
  5 in total

Review 1.  Towards a neurobiological understanding of pain in neurofibromatosis type 1: mechanisms and implications for treatment.

Authors:  Shreya S Bellampalli; Rajesh Khanna
Journal:  Pain       Date:  2019-05       Impact factor: 6.961

2.  Depression explains the association between pain intensity and pain interference among adults with neurofibromatosis.

Authors:  James D Doorley; Jonathan Greenberg; Jafar Bakhshaie; Nathan S Fishbein; Ana-Maria Vranceanu
Journal:  J Neurooncol       Date:  2021-08-19       Impact factor: 4.506

3.  Assessment of nociception and related quality-of-life measures in a porcine model of neurofibromatosis type 1.

Authors:  Rajesh Khanna; Aubin Moutal; Katherine A White; Aude Chefdeville; Pedro Negrao de Assis; Song Cai; Vicki J Swier; Shreya S Bellampalli; Marissa D Giunta; Benjamin W Darbro; Dawn E Quelle; Jessica C Sieren; Margaret R Wallace; Christopher S Rogers; David K Meyerholz; Jill M Weimer
Journal:  Pain       Date:  2019-11       Impact factor: 7.926

4.  Cannabidiol (CBD) for Treatment of Neurofibromatosis-related Pain and Concomitant Mood Disorder: A Case Report.

Authors:  Omar Hegazy; Howard Platnick
Journal:  Cureus       Date:  2019-12-06

5.  Health service experiences among adults with hereditary spastic paraparesis or neurofibromatosis type 1.

Authors:  Krister W Fjermestad; Øivind Kanavin; Livø Nyhus; Lise B Hoxmark
Journal:  Mol Genet Genomic Med       Date:  2020-09-14       Impact factor: 2.183

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.